Compare Adaptive Biotechnologies Corp (ADPT) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Xpeng Inc - ADR — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Xpeng Inc - ADR trades at $13.25 (market cap $12.75B). The key difference: Xpeng Inc - ADR is far larger — about 3.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ADPT | XPEV | |
|---|---|---|
Market Cap | $3.33B | $12.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $28.07 |
52-Week Low | $10.24 | $12.09 |
Enterprise Value | $3.19B | $14.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
XPeng (XPEV) trades at $13.17, up 0.69% today, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with negative profitability ratios. Recent news highlights vehicle delivery growth and advancements in autonomous driving technology, but the stock faces headwinds from broader EV sector challenges.
The outlook remains cautious due to persistent losses and competitive pressures, though analyst consensus is bullish with 64.7% buy ratings. Key risks include execution on profitability, intense EV competition, and regulatory uncertainties. Revenue expansion and technology innovation present opportunities if the company can achieve sustained margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
